U.S.

FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma

Food and Drug Administration · Official source · Updated 1h ago

Facts

Rybrevant Faspro is not indicated as a treatment for patients with oropharyngeal squamous cell carcinoma that is associated with human papillomavirus (HPV). ^[1]

Primary source

Food and Drug Administration

Published Nov 5, 2026